Summary

The global blood culture tests market is anticipated to grow from USD 6.66 billion in 2026 to USD 8.94 billion by 2031, reflecting a CAGR of 6.1%. Market growth is supported by the rising incidence of bloodstream infections (BSIs), sepsis, and healthcare-associated infections (HAIs), along with increasing concerns regarding antimicrobial resistance (AMR). Blood culture remains an important diagnostic approach for detecting viable microorganisms in the bloodstream and supporting appropriate antimicrobial treatment decisions. The increasing number of hospital admissions, surgical procedures, and critically ill and immunocompromised patients is further contributing to blood culture testing volumes. Additionally, the growing adoption of automated blood culture systems, rapid microbial identification technologies, and integrated microbiology workflows, coupled with expanding diagnostic laboratory infrastructure, is accelerating market growth. Consumables to register the highest CAGR in the blood culture tests market from 2026 to 2031 Based on product, the consumables segment is likely to record the highest CAGR during the forecast period. This segment is primarily driven by the recurring utilization of blood culture bottles, culture media, reagents, and other associated consumables required for routine blood culture testing. Unlike instruments, which are generally capital purchases with relatively long replacement cycles, blood culture bottles and related consumables are required for each test, creating sustained demand in proportion to testing volumes. Increasing diagnosis of sepsis and bloodstream infections, rising hospital and critical care admissions, and greater emphasis on early identification of causative pathogens are contributing to higher consumption across hospital microbiology and diagnostic laboratories. Furthermore, the expanding installed base of automated blood culture platforms is generating recurring demand for compatible aerobic, anaerobic, and pediatric blood culture bottles and media, further strengthening the segment’s position in the global market. Bacteremia segment captured the largest share of the blood culture tests market in 2025 Based on application, the bacteremia segment accounted for the largest market share in 2025, owing to the widespread use of blood cultures for the detection of bacterial bloodstream infections and identification of causative pathogens. Bacteremia can occur secondary to infections originating from the respiratory tract, urinary tract, gastrointestinal tract, skin and soft tissues, as well as from intravascular catheters and other invasive procedures, resulting in substantial testing demand across hospital settings. Blood culture remains a key diagnostic method for confirming viable bacteria in the bloodstream and obtaining isolates for subsequent pathogen identification and antimicrobial susceptibility testing (AST). Asia Pacific to register fastest growth rate in blood culture tests market between 2026 and 2031 Based on region, Asia Pacific is expected to witness the fastest growth rate during the forecast period. The regional market growth is supported by expanding healthcare infrastructure, increasing healthcare expenditure, and continued development of hospital and clinical laboratory capabilities across emerging economies. The substantial burden of infectious diseases, bloodstream infections, sepsis, and healthcare-associated infections, coupled with large patient populations and increasing hospital admissions, is driving demand for blood culture testing across the region. Governments and private healthcare providers are investing in diagnostic laboratory infrastructure, microbiology capabilities, hospital capacity, and healthcare accessibility, supporting a gradual transition from conventional workflows toward automated blood culture systems in several markets. Furthermore, growing awareness of antimicrobial resistance, antimicrobial stewardship, and the importance of early pathogen identification, along with increasing adoption of automated microbiology platforms and rapid diagnostic technologies, is contributing to market expansion. Major countries supporting regional growth include China, India, Japan, South Korea, and other rapidly developing Asia Pacific healthcare markets. Breakdown of primary participants in the blood culture tests market is as follows: ・ By Company Type: Tier 1 (31%), Tier 2 (40%), and Tier 3 (29%) ・ By Designation: C-level Executives (30%), Directors (24%), and Others (46%) ・ By Region: North America (52%), Europe (20%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%) Key players in the blood culture tests market are Waters Corporation (US), bioMérieux (France), Thermo Fisher Scientific, Inc. (US), DiaSorin S.p.A. (Italy), Danaher Corporation (US), Bruker Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Accelerate Diagnostics, Inc (US), and Autobio Diagnostics Co., Ltd (China). Research Coverage: This research report categorizes the blood culture tests market by product (consumables, instruments, and software & services), method (conventional/manual blood culture and automated blood culture), technology (culture-based, molecular, and proteomics), application (bacteremia, fungemia, and mycobacterial detection), end user (hospital laboratories, reference laboratories, academic research laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the blood culture tests market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, and key strategies, such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the market. This report covers the competitive analysis of upcoming startups in the blood culture tests ecosystem. Reasons to Buy This Report: The report will help leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall blood culture tests market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: ・ Analysis of key drivers (Increasing number of sepsis patients and cost of treatment, Rapid growth in geriatric population with chronic diseases, High incidence of nosocomial bloodstream infections, Growing demand for rapid diagnostic techniques with faster turnaround times, High prevalence of infectious diseases globally), restraints (High cost of automated blood culture instruments, Lack of trained laboratory technicians) opportunities (Growth opportunities in emerging economies, Increased need to identify antibiotic-resistant microorganisms) and Challenges (Long turnaround time associated with conventional blood culture workflows, Blood culture contamination and pre-analytical errors) influencing the blood culture tests market growth ・ Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the blood culture tests market ・ Market Development: Comprehensive information about lucrative markets; the report analyzes the blood culture tests market across varied regions ・ Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the blood culture tests market ・ Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Waters Corporation (US), bioMérieux (France), Thermo Fisher Scientific, Inc. (US), and DiaSorin S.p.A. (Italy)

ページTOPに戻る

Table of Contents

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKETS COVERED & REGIONAL SCOPE 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 41
1.4 CURRENCY CONSIDERED 41
1.5 STAKEHOLDERS 41
1.6 SUMMARY OF CHANGES 42
2 EXECUTIVE SUMMARY 43
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 43
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 44
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 45
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 46
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 47
3 PREMIUM INSIGHTS 48
3.1 BLOOD CULTURE TESTS MARKET OVERVIEW 48
3.2 BLOOD CULTURE TESTS MARKET, BY OFFERING, 2026 VS. 2031 49
3.3 BLOOD CULTURE TESTS MARKET, BY METHOD, 2026 VS. 2031 49
3.4 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2026 VS. 2031 50
3.5 BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2026 VS. 2031 50
3.6 BLOOD CULTURE TESTS MARKET, BY END USER, 2026 VS. 2031 51
3.7 BLOOD CULTURE TESTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
4 MARKET OVERVIEW 52
4.1 INTRODUCTION 52
4.2 MARKET DYNAMICS 52
4.2.1 DRIVERS 53
4.2.1.1 Increasing number of sepsis patients and rising cost of treatment 53
4.2.1.2 Rapid growth in geriatric population with chronic diseases 53
4.2.1.3 High incidence of bloodstream infections 53
4.2.1.4 Growing demand for rapid diagnostic techniques 54
4.2.1.5 High prevalence of infectious diseases 54
4.2.2 RESTRAINTS 55
4.2.2.1 High cost of automated blood culture instruments 55
4.2.2.2 Lack of trained laboratory technicians 56
4.2.3 OPPORTUNITIES 56
4.2.3.1 Growth opportunities in emerging economies 56
4.2.3.2 Increased need to identify antibiotic-resistant microorganisms 57
4.2.4 CHALLENGES 57
4.2.4.1 Long turnaround time associated with conventional blood culture workflows 57
4.2.4.2 Blood culture contamination and pre-analytical errors 58
4.3 UNMET NEEDS & WHITE SPACES 58
4.3.1 UNMET NEEDS IN BLOOD CULTURE TESTS MARKET 58
4.3.2 WHITE SPACE OPPORTUNITIES 59
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60
4.4.1 INTERCONNECTED MARKETS 60
4.4.2 CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 62
4.5.1 KEY MOVES & STRATEGIC FOCUS 62
5 INDUSTRY TRENDS 63
5.1 PORTER’S FIVE FORCES ANALYSIS 63
5.1.1 BARGAINING POWER OF SUPPLIERS 64
5.1.2 BARGAINING POWER OF BUYERS 64
5.1.3 THREAT OF NEW ENTRANTS 64
5.1.4 THREAT OF SUBSTITUTES 64
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 64
5.2 MACROECONOMIC INDICATORS 65
5.2.1 INTRODUCTION 65
5.2.2 GDP TRENDS & FORECAST 65
5.3 SUPPLY CHAIN ANALYSIS 66
5.4 VALUE CHAIN ANALYSIS 68
5.5 ECOSYSTEM ANALYSIS 69
5.5.1 BLOOD CULTURE TESTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 70
5.6 PRICING ANALYSIS 70
5.6.1 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS,
BY KEY PLAYER, 2024–2026 71
5.6.2 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS,
BY REGION, 2024–2026 72
5.7 TRADE ANALYSIS 73
5.7.1 IMPORT SCENARIO (HS CODE 382100) 73
5.7.2 EXPORT SCENARIO (HS CODE 382100) 74
5.8 KEY CONFERENCES & EVENTS, 2026–2027 74
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
5.10 INVESTMENT & FUNDING SCENARIO 76
5.11 CASE STUDY ANALYSIS 76
5.11.1 ENHANCED STAINING AND WORKFLOW PROTOCOLS IMPROVE DETECTION OF FASTIDIOUS ORGANISMS IN POSITIVE BLOOD CULTURES 76
5.11.2 RAPID BLOOD CULTURE IDENTIFICATION AND ANTIMICROBIAL STEWARDSHIP REDUCE TIME TO OPTIMAL THERAPY 77
5.12 IMPACT OF 2025 US TARIFFS ON BLOOD CULTURE TESTS MARKET 78
5.12.1 INTRODUCTION 78
5.12.2 KEY TARIFF RATES 78
5.12.3 PRICE IMPACT ANALYSIS 79
5.12.4 IMPACT ON REGION 79
5.12.4.1 North America 79
5.12.4.2 Europe 79
5.12.4.3 Asia Pacific 79
5.12.5 IMPACT ON END-USE INDUSTRIES 80
5.12.5.1 Hospital laboratories 80
5.12.5.2 Reference laboratories 80
5.12.5.3 Academic research laboratories 80
5.12.5.4 Other end users 80
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 81
6.1 KEY TECHNOLOGIES 81
6.1.1 CULTURE-BASED TECHNOLOGIES 81
6.1.2 MOLECULAR TECHNOLOGIES 81
6.2 COMPLEMENTARY TECHNOLOGIES 81
6.2.1 RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING 81
6.3 TECHNOLOGY/PRODUCT ROADMAP 82
6.4 PATENT ANALYSIS 83
6.4.1 LIST OF MAJOR PATENTS 84
6.5 FUTURE APPLICATIONS 84
6.6 IMPACT OF AI/GENERATIVE AI ON BLOOD CULTURE TESTS MARKET 85
6.6.1 INTRODUCTION 85
6.6.2 TOP USE CASES & MARKET POTENTIAL 86
6.6.3 KEY COMPANIES IMPLEMENTING AI 87
6.6.4 FUTURE OF AI 87
7 SUSTAINABILITY & REGULATORY LANDSCAPE 88
7.1 REGIONAL REGULATIONS & COMPLIANCE 88
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
7.1.2 INDUSTRY STANDARDS 90
7.2 SUSTAINABILITY INITIATIVES 91
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES IN BLOOD CULTURE TESTS 91
7.2.1.1 Eco-friendly initiatives 91
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 92
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 93
8.1 DECISION-MAKING PROCESS 93
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 93
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 93
8.2.2 BUYING CRITERIA 94
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 94
8.4 UNMET NEEDS ACROSS VARIOUS END USERS 96
8.5 MARKET PROFITABILITY 97
8.5.1 REVENUE POTENTIAL 97
8.5.2 COST DYNAMICS 97
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 97
9 BLOOD CULTURE TESTS MARKET, BY OFFERING 99
9.1 INTRODUCTION 100
9.2 CONSUMABLES 100
9.2.1 BLOOD CULTURE MEDIA 102
9.2.1.1 Aerobic blood culture media 105
9.2.1.1.1 Growing blood culture volumes to support aerobic media market growth 105
9.2.1.2 Pediatric aerobic blood culture media 108
9.2.1.2.1 Rising pediatric sepsis burden to drive demand for specialized low-volume blood culture bottles 108
9.2.1.3 Anaerobic blood culture media 110
9.2.1.3.1 Increased need for routine diagnosis of bacteria in blood culture to drive segment 110
9.2.1.4 Mycobacterial blood culture media 113
9.2.1.4.1 Persistent global TB burden to drive demand for mycobacterial blood culture media 113
9.2.1.5 Fungi/yeast blood culture media 115
9.2.1.5.1 Easy identification and characterization of special fungal species to drive segment 115
9.2.2 ASSAY KITS & REAGENTS 117
9.2.2.1 Increased need for rapid identification of bacteria and yeast from positive blood cultures to drive market 117
9.2.3 BLOOD CULTURE ACCESSORIES 119
9.2.3.1 Growing number of blood culture tests to drive market 119
9.3 INSTRUMENTS 122
9.3.1 AUTOMATED BLOOD CULTURE SYSTEMS 125
9.3.1.1 Need for automated imaging systems and advanced algorithms to drive market 125
9.3.2 SUPPORTING LABORATORY EQUIPMENT 128
9.3.2.1 Incubators 130
9.3.2.1.1 Incubators to provide optimal environment with adequate temperature and oxygen levels for microbial growth 130
9.3.2.2 Colony counters 132
9.3.2.2.1 Colony counters to increase direct image scanning and analysis capability 132
9.3.2.3 Microscopes 134
9.3.2.3.1 Growing emphasis on rapid preliminary identification to fuel demand for microscopes 134
9.3.2.4 Gram stainers 136
9.3.2.4.1 Gram strainers to guide initial antibiotic section and appropriate empirical therapy 136
9.3.2.5 Other supporting equipment 139
9.4 SOFTWARE & SERVICES 141
9.4.1 INCREASED NEED FOR AUTOMATED SYSTEMS IN HOSPITAL-BASED LABORATORIES TO DRIVE MARKET 141
10 BLOOD CULTURE TESTS MARKET, BY METHOD 144
10.1 INTRODUCTION 145
10.2 CONVENTIONAL/MANUAL BLOOD CULTURES 145
10.2.1 LOWER CAPITAL REQUIREMENTS TO DRIVE ADOPTION OF CONVENTIONAL BLOOD CULTURE METHODS IN RESOURCE-CONSTRAINED SETTINGS 145
10.3 AUTOMATED BLOOD CULTURES 148
10.3.1 NEED FOR FASTER TURNAROUND TIMES TO FUEL TRANSITION TOWARD AUTOMATED BLOOD CULTURE METHODS 148
11 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY 152
11.1 INTRODUCTION 153
11.2 CULTURE-BASED TECHNOLOGIES 153
11.2.1 ADVANCEMENTS IN AUTOMATED DETECTION TO STRENGTHEN CULTURE-BASED TECHNOLOGIES SEGMENT 153
11.3 MOLECULAR TECHNOLOGIES 156
11.3.1 PCR 158
11.3.1.1 Reduced risk of contamination and easy detection of bloodstream infections to drive segment 158
11.3.2 MICROARRAYS 161
11.3.2.1 Determination of better genotyping characterization and identification of bacterial infections to drive segment 161
11.3.3 PNA-FISH 163
11.3.3.1 Rapid species-level identification to strengthen role of PNA-FISH in bloodstream infection diagnosis 163
11.4 OTHER TECHNOLOGIES 165
12 BLOOD CULTURE TESTS MARKET, BY APPLICATION 168
12.1 INTRODUCTION 169
12.2 BACTEREMIA 169
12.2.1 GROWING INCIDENCE OF SEPSIS CASES GLOBALLY TO DRIVE MARKET 169
12.3 FUNGEMIA 171
12.3.1 INCREASING INCIDENCE OF BLOODSTREAM INFECTIONS TO DRIVE MARKET 171
12.4 MYCOBACTERIAL DETECTION 174
12.4.1 HIGH GLOBAL TB BURDEN AND CONCENTRATION OF CASES IN HIGH-RISK POPULATIONS TO DRIVE DEMAND 174
13 BLOOD CULTURE TESTS MARKET, BY END USER 177
13.1 INTRODUCTION 178
13.2 HOSPITAL LABORATORIES 178
13.2.1 INCREASED ABILITY TO CONDUCT LARGE VOLUME OF BLOOD CULTURE TESTS TO DRIVE MARKET 178
13.3 REFERENCE LABORATORIES 181
13.3.1 GROWING REFERRAL AND SPECIALIZED TESTING NEEDS TO FUEL REFERENCE LABORATORY DEMAND 181
13.4 ACADEMIC RESEARCH LABORATORIES 183
13.4.1 GROWING FOCUS ON NOVEL DIAGNOSTIC DEVELOPMENT TO FUEL BLOOD CULTURE TESTING IN RESEARCH LABORATORIES 183
13.5 OTHER END USERS 185
14 BLOOD CULTURE TESTS MARKET, BY REGION 188
14.1 INTRODUCTION 189
14.2 NORTH AMERICA 190
14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 195
14.2.2 US 196
14.2.2.1 Rising sepsis burden and antimicrobial resistance to drive demand for blood culture testing in US 196
14.2.3 CANADA 200
14.2.3.1 Increasing MRSA bloodstream infection burden to strengthen demand 200
14.3 BLOOD CULTURE TESTS MARKET: VOLUME ANALYSIS 205
14.3.1 INTRODUCTION 205
14.3.2 NORTH AMERICA: BLOOD CULTURE SETS VOLUME 205
14.4 EUROPE 206
14.4.1 EUROPE: MACROECONOMIC OUTLOOK 210
14.4.2 GERMANY 211
14.4.2.1 Expanding healthcare investment and inpatient care spending to drive adoption 211
14.4.3 UK 215
14.4.3.1 Rising AMR-related bacteremia and E. coli prevalence to expand blood culture testing 215
14.4.4 FRANCE 219
14.4.4.1 Rising healthcare expenditure and high physician density to strengthen adoption 219
14.4.5 ITALY 223
14.4.5.1 Expanding microbiology surveillance and continued healthcare investment to support Italy’s market 223
14.4.6 SPAIN 228
14.4.6.1 Growing elderly population and healthcare utilization to sustain demand 228
14.4.7 REST OF EUROPE 232
14.5 ASIA PACIFIC 237
14.5.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 242
14.5.2 CHINA 242
14.5.2.1 Expanding healthcare investment and hospital capacity to drive blood culture testing demand in China 242
14.5.3 JAPAN 247
14.5.3.1 Extensive hospital infrastructure to sustain demand 247
14.5.4 INDIA 251
14.5.4.1 Rising government healthcare expenditure to support expansion of diagnostic and laboratory infrastructure 251
14.5.5 REST OF ASIA PACIFIC 255
14.6 LATIN AMERICA 260
14.6.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 264
14.6.2 BRAZIL 265
14.6.2.1 Growth in hospital-service expenditure to support modernization of Brazil's clinical diagnostic infrastructure 265
14.6.3 MEXICO 269
14.6.3.1 Strengthening AMR laboratory requirements to support adoption 269
14.6.4 REST OF LATIN AMERICA 273
14.7 MIDDLE EAST & AFRICA 278
14.7.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 278
15 COMPETITIVE LANDSCAPE 283
15.1 INTRODUCTION 283
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 283
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BLOOD CULTURE TESTS MARKET 283
15.3 REVENUE ANALYSIS, 2023–2025 285
15.4 MARKET SHARE ANALYSIS, 2025 285
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 288
15.5.1 STARS 288
15.5.2 EMERGING LEADERS 288
15.5.3 PERVASIVE PLAYERS 288
15.5.4 PARTICIPANTS 288
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 290
15.5.5.1 Company footprint 290
15.5.5.2 Region footprint 290
15.5.5.3 Offering footprint 291
15.5.5.4 Method footprint 291
15.5.5.5 Technology footprint 292
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 292
15.6.1 PROGRESSIVE COMPANIES 292
15.6.2 RESPONSIVE COMPANIES 292
15.6.3 DYNAMIC COMPANIES 293
15.6.4 STARTING BLOCKS 293
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 294
15.6.5.1 Detailed list of key startups/SMEs 294
15.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 294
15.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 295
15.7 COMPANY VALUATION & FINANCIAL METRICS 295
15.7.1 FINANCIAL METRICS 295
15.7.2 COMPANY VALUATION 296
15.8 BRAND/PRODUCT COMPARISON 296
15.9 COMPETITIVE SCENARIO 297
15.9.1 PRODUCT LAUNCHES & APPROVALS 297
15.9.2 DEALS 298
16 COMPANY PROFILES 299
16.1 KEY PLAYERS 299
16.1.1 WATERS CORPORATION 299
16.1.1.1 Business overview 299
16.1.1.2 Products offered 300
16.1.1.3 Recent developments 302
16.1.1.3.1 Product approvals 302
16.1.1.3.2 Deals 302
16.1.1.4 MnM view 303
16.1.1.4.1 Right to win 303
16.1.1.4.2 Strategic choices 303
16.1.1.4.3 Weaknesses & competitive threats 303
16.1.2 BIOMÉRIEUX 304
16.1.2.1 Business overview 304
16.1.2.2 Products offered 305
16.1.2.3 Recent developments 307
16.1.2.3.1 Product launches 307
16.1.2.4 MnM view 307
16.1.2.4.1 Right to win 307
16.1.2.4.2 Strategic choices 307
16.1.2.4.3 Weaknesses & competitive threats 307
16.1.3 THERMO FISHER SCIENTIFIC, INC. 308
16.1.3.1 Business overview 308
16.1.3.2 Products offered 309
16.1.3.3 Recent developments 310
16.1.3.3.1 Deals 310
16.1.3.4 MnM view 311
16.1.3.4.1 Right to win 311
16.1.3.4.2 Strategic choices 311
16.1.3.4.3 Weaknesses & competitive threats 311
16.1.4 DANAHER CORPORATION 312
16.1.4.1 Business overview 312
16.1.4.2 Products offered 313
16.1.4.3 MnM view 314
16.1.4.3.1 Right to win 314
16.1.4.3.2 Strategic choices 314
16.1.4.3.3 Weaknesses & competitive threats 314
16.1.5 F. HOFFMANN-LA ROCHE LTD. 315
16.1.5.1 Business overview 315
16.1.5.2 Products offered 316
16.1.5.3 Recent developments 317
16.1.5.3.1 Product launches 317
16.1.5.4 MnM view 318
16.1.5.4.1 Right to win 318
16.1.5.4.2 Strategic choices 318
16.1.5.4.3 Weaknesses & competitive threats 318
16.1.6 DIASORIN S.P.A. 319
16.1.6.1 Business overview 319
16.1.6.2 Products offered 320
16.1.6.3 Recent developments 322
16.1.6.3.1 Product approvals 322
16.1.7 BRUKER CORPORATION 323
16.1.7.1 Business overview 323
16.1.7.2 Products offered 324
16.1.7.3 Recent developments 325
16.1.7.3.1 Product launches & approvals 325
16.1.7.3.2 Deals 326
16.1.8 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 327
16.1.8.1 Business overview 327
16.1.8.2 Products offered 328
16.1.8.3 Recent developments 329
16.1.8.3.1 Product launches 329
16.1.9 AUTOBIO DIAGNOSTICS CO., LTD. 330
16.1.9.1 Business overview 330
16.1.9.2 Products offered 331
16.1.9.3 Recent developments 332
16.1.9.3.1 Deals 332
16.1.10 SCENKER BIOLOGICAL TECHNOLOGY CO., LTD. 333
16.1.10.1 Business overview 333
16.1.10.2 Products offered 334
16.2 OTHER PLAYERS 335
16.2.1 HIMEDIA LABORATORIES PVT. LTD. 335
16.2.2 BIOBASE GROUP 336
16.2.3 LABOTRONICS SCIENTIFIC 337
16.2.4 HARDY DIAGNOSTICS 338
16.2.5 BIOLOG, INC. 339
16.2.6 ZHUHAI DEER BIOENGINEERING CO., LTD. 340
16.2.7 ZHUHAI MEIHUA MEDICAL TECHNOLOGY CO. LTD. 341
16.2.8 FISON INSTRUMENTS LTD. 342
16.2.9 BINDER GMBH 343
16.2.10 LABTRON EQUIPMENT LTD. 344
16.2.11 LABNICS LTD. 345
16.2.12 COPAN ITALIA S.P.A. 346
16.2.13 GREINER BIO-ONE INTERNATIONAL GMBH 347
16.2.14 LIOFILCHEM S.R.L. 348
16.2.15 TITAN BIOTECH LTD. 349
17 RESEARCH METHODOLOGY 350
17.1 RESEARCH DATA 350
17.2 RESEARCH APPROACH 350
17.2.1 SECONDARY RESEARCH 350
17.2.1.1 Key data from secondary sources 351
17.2.2 PRIMARY DATA 352
17.2.2.1 Key data from primary sources 354
17.2.2.2 Key industry insights 355
17.3 MARKET SIZE ESTIMATION 356
17.3.1 BOTTOM-UP APPROACH 357
17.3.1.1 Approach 1: Company revenue estimation approach 357
17.3.1.2 Approach 2: Presentations of companies and primary interviews 357
17.3.1.3 Growth forecast 358
17.3.2 TOP-DOWN APPROACH 358
17.4 MARKET BREAKDOWN & DATA TRIANGULATION 360
17.5 MARKET SHARE ANALYSIS 361
17.6 RESEARCH ASSUMPTIONS 361
17.6.1 GROWTH RATE ASSUMPTIONS 361
17.7 RESEARCH LIMITATIONS 362
17.8 RISK ASSESSMENT 362
18 APPENDIX 363
18.1 DISCUSSION GUIDE 363
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 368
18.3 CUSTOMIZATION OPTIONS 370
18.4 RELATED REPORTS 370
18.5 AUTHOR DETAILS 371

ページTOPに戻る

List of Tables/Graphs

TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV, ALL AGES, 2010, 2023, AND 2024 (MILLION PEOPLE) 55.
TABLE 2 TOTAL TUBERCULOSIS INCIDENCE, BY REGION, 2024 55.
TABLE 3 BLOOD CULTURE TESTS MARKET: PORTER’S FIVE FORCES ANALYSIS 64.
TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 65.
TABLE 5 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 71.
TABLE 6 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS, BY REGION, 2024–2026 (USD) 72.
TABLE 7 IMPORT DATA FOR HS CODE 382100-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 73.
TABLE 8 EXPORT DATA FOR HS CODE 382100-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 74.
TABLE 9 BLOOD CULTURE TESTS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 74.
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES 78.
TABLE 11 LIST OF MAJOR PATENTS PERTAINING TO BLOOD CULTURE TESTS MARKET, 2023–2025 84.
TABLE 12 KEY COMPANIES IMPLEMENTING AI IN BLOOD CULTURE TESTS MARKET 87.
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88.
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88.
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89.
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89.
TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90.
TABLE 18 GLOBAL STANDARDS IN BLOOD CULTURE TESTS MARKET 90.
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 93.
TABLE 20 KEY BUYING CRITERIA, BY OFFERING 94.
TABLE 21 ADOPTION BARRIERS & INTERNAL CHALLENGES 95.
TABLE 22 BLOOD CULTURE TESTS MARKET: UNMET NEEDS ACROSS VARIOUS END USERS 96.
TABLE 23 BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 100.
TABLE 24 BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 100.
TABLE 25 BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 101.
TABLE 26 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 101.
TABLE 27 EUROPE: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 101.
TABLE 28 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 102.
TABLE 29 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 102.
TABLE 30 EXAMPLES OF BLOOD CULTURE MEDIA 103.
TABLE 31 BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 103.
TABLE 32 BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 104.
TABLE 33 NORTH AMERICA: BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 104.
TABLE 34 EUROPE: BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 104.
TABLE 35 ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 105.
TABLE 36 LATIN AMERICA: BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 105.
TABLE 37 AEROBIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 106.
TABLE 38 NORTH AMERICA: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 106.
TABLE 39 EUROPE: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107.
TABLE 40 ASIA PACIFIC: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107.
TABLE 41 LATIN AMERICA: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107.
TABLE 42 PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 109.
TABLE 43 NORTH AMERICA: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109.
TABLE 44 EUROPE: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109.
TABLE 45 ASIA PACIFIC: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110.
TABLE 46 LATIN AMERICA: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110.
TABLE 47 ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 111.
TABLE 48 NORTH AMERICA: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111.
TABLE 49 EUROPE: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112.
TABLE 50 ASIA PACIFIC: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112.
TABLE 51 LATIN AMERICA: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112.
TABLE 52 MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 113.
TABLE 53 NORTH AMERICA: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 114.
TABLE 54 EUROPE: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 114.
TABLE 55 ASIA PACIFIC: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 114.
TABLE 56 LATIN AMERICA: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115.
TABLE 57 FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 115.
TABLE 58 NORTH AMERICA: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 59 EUROPE: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 60 ASIA PACIFIC: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 61 LATIN AMERICA: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 62 EXAMPLES OF BLOOD CULTURE ASSAY KITS & REAGENTS 117.
TABLE 63 BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 118.
TABLE 64 NORTH AMERICA: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 65 EUROPE: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 66 ASIA PACIFIC: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 67 LATIN AMERICA: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 68 EXAMPLES OF BLOOD CULTURE ACCESSORIES 120.
TABLE 69 BLOOD CULTURE ACCESSORIES MARKET, BY REGION, 2024–2031 (USD MILLION) 120.
TABLE 70 NORTH AMERICA: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 71 EUROPE: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 72 ASIA PACIFIC: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 73 LATIN AMERICA: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122.
TABLE 74 BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 123.
TABLE 75 BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 123.
TABLE 76 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 123.
TABLE 77 EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 78 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 79 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 80 EXAMPLES OF AUTOMATED BLOOD CULTURE SYSTEMS 125.
TABLE 81 AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 126.
TABLE 82 NORTH AMERICA: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126.
TABLE 83 EUROPE: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 84 ASIA PACIFIC: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 85 LATIN AMERICA: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 86 SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 128.
TABLE 87 SUPPORTING LABORATORY EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 128.
TABLE 88 NORTH AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 89 EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 90 ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 91 LATIN AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130.
TABLE 92 INCUBATORS MARKET, BY REGION, 2024–2031 (USD MILLION) 131.
TABLE 93 NORTH AMERICA: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131.
TABLE 94 EUROPE: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131.
TABLE 95 ASIA PACIFIC: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 96 LATIN AMERICA: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 97 COLONY COUNTERS MARKET, BY REGION, 2024–2031 (USD MILLION) 133.
TABLE 98 NORTH AMERICA: COLONY COUNTERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133.
TABLE 99 EUROPE: COLONY COUNTERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133.
TABLE 100 ASIA PACIFIC: COLONY COUNTERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134.
TABLE 101 LATIN AMERICA: COLONY COUNTERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134.
TABLE 102 MICROSCOPES MARKET, BY REGION, 2024–2031 (USD MILLION) 135.
TABLE 103 NORTH AMERICA: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 104 EUROPE: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 105 ASIA PACIFIC: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 106 LATIN AMERICA: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 107 GRAM STAINERS MARKET, BY REGION, 2024–2031 (USD MILLION) 137.
TABLE 108 NORTH AMERICA: GRAM STAINERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 109 EUROPE: GRAM STAINERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 110 ASIA PACIFIC: GRAM STAINERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 111 LATIN AMERICA: GRAM STAINERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 112 OTHER SUPPORTING EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 113 NORTH AMERICA: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 114 EUROPE: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 115 ASIA PACIFIC: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 116 LATIN AMERICA: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 117 BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION) 141.
TABLE 118 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 119 EUROPE: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 120 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 121 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 143.
TABLE 122 BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 145.
TABLE 123 EXAMPLES OF CONVENTIONAL/MANUAL BLOOD CULTURE PRODUCTS 146.
TABLE 124 CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY REGION, 2024–2031 (USD MILLION) 147.
TABLE 125 NORTH AMERICA: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 126 EUROPE: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 127 ASIA PACIFIC: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 128 LATIN AMERICA: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 129 EXAMPLES OF AUTOMATED BLOOD CULTURE PRODUCTS 149.
TABLE 130 AUTOMATED BLOOD CULTURES MARKET, BY REGION, 2024–2031 (USD MILLION) 149.
TABLE 131 NORTH AMERICA: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 132 EUROPE: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 133 ASIA PACIFIC: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 134 LATIN AMERICA: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 135 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 153.
TABLE 136 BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 154.
TABLE 137 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 138 EUROPE: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 155.
TABLE 139 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 155.
TABLE 140 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 155.
TABLE 141 BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 156.
TABLE 142 BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 157.
TABLE 143 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 144 EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 145 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 146 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 147 BLOOD CULTURE TESTS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION) 159.
TABLE 148 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 149 EUROPE: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 150 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 151 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 152 BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY REGION, 2024–2031 (USD MILLION) 161.
TABLE 153 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 154 EUROPE: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 155 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 156 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 157 BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY REGION, 2024–2031 (USD MILLION) 164.
TABLE 158 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 159 EUROPE: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 160 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 165.
TABLE 161 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 165.
TABLE 162 EXAMPLES OF MALDI-TOF MS SYSTEMS 166.
TABLE 163 BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 166.
TABLE 164 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 165 EUROPE: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 166 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 167 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 168 BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 169.
TABLE 169 BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY REGION, 2024–2031 (USD MILLION) 170.
TABLE 170 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 171 EUROPE: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 172 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 173 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 174 BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY REGION, 2024–2031 (USD MILLION) 172.
TABLE 175 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 176 EUROPE: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 177 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 178 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 179 BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY REGION, 2024–2031 (USD MILLION) 175.
TABLE 180 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 181 EUROPE: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 182 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 183 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 184 BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 178.
TABLE 185 BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 179.
TABLE 186 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 187 EUROPE: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 188 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 189 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 190 BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 181.
TABLE 191 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 192 EUROPE: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 193 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 194 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 195 BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 184.
TABLE 196 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 197 EUROPE: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 198 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 199 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 200 BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 186.
TABLE 201 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 202 EUROPE: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 203 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 204 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 205 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY REGION, 2024–2031 (USD MILLION) 189.
TABLE 206 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 207 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 192.
TABLE 208 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 192.
TABLE 209 NORTH AMERICA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 192.
TABLE 210 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 193.
TABLE 211 NORTH AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 193.
TABLE 212 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 193.
TABLE 213 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 194.
TABLE 214 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 194.
TABLE 215 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194.
TABLE 216 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 195.
TABLE 217 NORTH AMERICA: MACROECONOMIC INDICATORS 195.
TABLE 218 US: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 196.
TABLE 219 US: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 197.
TABLE 220 US: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 197.
TABLE 221 US: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 198.
TABLE 222 US: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 198.
TABLE 223 US: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 198.
TABLE 224 US: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 199.
TABLE 225 US: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 199.
TABLE 226 US: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 199.
TABLE 227 US: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 200.
TABLE 228 CANADA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 201.
TABLE 229 CANADA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 201.
TABLE 230 CANADA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 202.
TABLE 231 CANADA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 202.
TABLE 232 CANADA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 203.
TABLE 233 CANADA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 203.
TABLE 234 CANADA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 203.
TABLE 235 CANADA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 204.
TABLE 236 CANADA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 204.
TABLE 237 CANADA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 204.
TABLE 238 NORTH AMERICA: BLOOD CULTURE SETS VOLUME, 2024–2031 (MN UNITS) 205.
TABLE 239 EUROPE: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 240 EUROPE: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 207.
TABLE 241 EUROPE: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 207.
TABLE 242 EUROPE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 207.
TABLE 243 EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 208.
TABLE 244 EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 208.
TABLE 245 EUROPE: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 208.
TABLE 246 EUROPE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 209.
TABLE 247 EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 209.
TABLE 248 EUROPE: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 209.
TABLE 249 EUROPE: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 210.
TABLE 250 EUROPE: MACROECONOMIC INDICATORS 210.
TABLE 251 GERMANY: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 211.
TABLE 252 GERMANY: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 212.
TABLE 253 GERMANY: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 212.
TABLE 254 GERMANY: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 212.
TABLE 255 GERMANY: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 213.
TABLE 256 GERMANY: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 213.
TABLE 257 GERMANY: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 213.
TABLE 258 GERMANY: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 214.
TABLE 259 GERMANY: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 214.
TABLE 260 GERMANY: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 214.
TABLE 261 UK: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 216.
TABLE 262 UK: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 216.
TABLE 263 UK: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 216.
TABLE 264 UK: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 217.
TABLE 265 UK: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 217.
TABLE 266 UK: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 217.
TABLE 267 UK: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 218.
TABLE 268 UK: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 218.
TABLE 269 UK: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218.
TABLE 270 UK: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 219.
TABLE 271 FRANCE: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 220.
TABLE 272 FRANCE: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 220.
TABLE 273 FRANCE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 220.
TABLE 274 FRANCE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 221.
TABLE 275 FRANCE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 221.
TABLE 276 FRANCE: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 221.
TABLE 277 FRANCE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 222.
TABLE 278 FRANCE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 222.
TABLE 279 FRANCE: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 222.
TABLE 280 FRANCE: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 223.
TABLE 281 ITALY: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 224.
TABLE 282 ITALY: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 224.
TABLE 283 ITALY: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 225.
TABLE 284 ITALY: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 225.
TABLE 285 ITALY: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 226.
TABLE 286 ITALY: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 226.
TABLE 287 ITALY: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 226.
TABLE 288 ITALY: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 227.
TABLE 289 ITALY: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 227.
TABLE 290 ITALY: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 227.
TABLE 291 SPAIN: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 228.
TABLE 292 SPAIN: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 229.
TABLE 293 SPAIN: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 229.
TABLE 294 SPAIN: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 229.
TABLE 295 SPAIN: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 230.
TABLE 296 SPAIN: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 230.
TABLE 297 SPAIN: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 230.
TABLE 298 SPAIN: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 231.
TABLE 299 SPAIN: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 231.
TABLE 300 SPAIN: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 231.
TABLE 301 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 233.
TABLE 302 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 233.
TABLE 303 REST OF EUROPE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 234.
TABLE 304 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 234.
TABLE 305 REST OF EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 235.
TABLE 306 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 235.
TABLE 307 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 235.
TABLE 308 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 236.
TABLE 309 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 236.
TABLE 310 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 236.
TABLE 311 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 238.
TABLE 312 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 238.
TABLE 313 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 238.
TABLE 314 ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 239.
TABLE 315 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 239.
TABLE 316 ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 240.
TABLE 317 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 240.
TABLE 318 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 240.
TABLE 319 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 241.
TABLE 320 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 241.
TABLE 321 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 241.
TABLE 322 ASIA PACIFIC: MACROECONOMIC INDICATORS 242.
TABLE 323 CHINA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 243.
TABLE 324 CHINA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 243.
TABLE 325 CHINA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 244.
TABLE 326 CHINA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 244.
TABLE 327 CHINA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 245.
TABLE 328 CHINA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 245.
TABLE 329 CHINA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 245.
TABLE 330 CHINA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 246.
TABLE 331 CHINA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246.
TABLE 332 CHINA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 246.
TABLE 333 JAPAN: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 247.
TABLE 334 JAPAN: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 335 JAPAN: BLOOD CULTURE MEDI